Article info
Neuropsychiatry
Research paper
Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years
- Correspondence to Dr Hideyuki Sawada, Clinical Research Center and Department of Neurology, Utano National Hospital, Kyoto 6168255, Japan; sawada.unh{at}gmail.com
Citation
Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years
Publication history
- Received January 28, 2018
- Revised April 27, 2018
- Accepted July 10, 2018
- First published August 3, 2018.
Online issue publication
November 21, 2018
Article Versions
- Previous version (3 August 2018).
- Previous version (3 September 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/